← Back to guidelines
Cardiology12 papers

Acute lead nephropathy

Last edited: 4/15/2026

Overview

Acute lead nephropathy is a chronic tubulointerstitial renal disease often presenting with modest proteinuria, frequently associated with hyperuricemia, gout, and hypertension, even in the absence of acute lead intoxication 12.

Diagnosis

  • Key Diagnostic Criteria: Occult lead poisoning leading to renal disease, often unrecognized due to lack of acute intoxication symptoms 2.
  • Recommended Tests:
  • - EDTA (calcium disodium edetate) lead mobilization test to assess body lead stores 12. - Renal biopsy to confirm tubulointerstitial damage 1.
  • Grading: Diagnosis relies heavily on elevated lead stores detected by EDTA test rather than solely on blood lead levels 2.
  • Management

  • First-Line Treatments:
  • - Chelation therapy with EDTA for reversing early stages of lead nephropathy 1.
  • Adjunctive Treatments:
  • - Management of associated conditions such as hypertension and gout 1. - Specific drug doses not detailed in abstracts.

    Special Populations

  • Hypertension and Gout: Common comorbidities in affected individuals, requiring concurrent management 1.
  • No specific guidance provided for pregnancy, pediatrics, or elderly populations 12.
  • Key Recommendations

  • Utilize the EDTA lead mobilization test for diagnosing occult lead nephropathy in patients with renal disease, gout, or hypertension (Evidence: Moderate) 12.
  • Chelation therapy with EDTA is safe and recommended for early stages of lead nephropathy to potentially reverse renal damage (Evidence: Moderate) 1.
  • Prevention of lead exposure remains the best strategy to avoid lead nephropathy (Evidence: Expert opinion) 1.
  • References

    1 Batuman V. Lead nephropathy, gout, and hypertension. The American journal of the medical sciences 1993. link 2 Wedeen RP. Use of the CaNa2 EDTA Pb-mobilization test to detect occult lead nephropathy. Uremia investigation 1985. link

    Original source

    1. [1]
      Lead nephropathy, gout, and hypertension.Batuman V The American journal of the medical sciences (1993)
    2. [2]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG